NEKTAR THERAPEUTICS Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Nektar Therapeutics quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2018 to Q2 2024.
  • Nektar Therapeutics Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $9.24M, a 68.2% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $9.24M -$19.8M -68.2% Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $17.3M -$24.9M -59.1% Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $18M -$35.4M -66.3% Dec 31, 2023 10-Q 2024-08-09
Q3 2023 $18.7M -$47.1M -71.6% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $29M -$40M -57.9% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $42.2M -$72.1M -63.1% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $53.4M -$63.6M -54.3% Dec 31, 2022 10-K 2024-03-05
Q3 2022 $65.9M -$53.8M -45% Sep 30, 2022 10-Q 2022-11-04
Q2 2022 $69M -$53.4M -43.6% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $114M -$10.7M -8.54% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $117M -$9.45M -7.47% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $120M -$9.27M -7.19% Sep 30, 2021 10-Q 2021-11-05
Q2 2021 $122M -$9.1M -6.92% Jun 30, 2021 10-Q 2021-08-06
Q1 2021 $125M -$8.93M -6.67% Mar 31, 2021 10-Q 2021-05-07
Q4 2020 $126M -$7.7M -5.74% Dec 31, 2020 10-K 2022-03-01
Q3 2020 $129M -$5.9M -4.38% Sep 30, 2020 10-Q 2020-11-06
Q2 2020 $131M +$49.3M +60% Jun 30, 2020 10-Q 2020-08-07
Q1 2020 $134M +$50.4M +60.4% Mar 31, 2020 10-Q 2020-05-08
Q4 2019 $134M +$134M Dec 31, 2019 10-K 2021-02-26
Q3 2019 $135M Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $82.2M Jun 30, 2019 10-Q 2019-08-09
Q1 2019 $83.5M Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $0 Dec 31, 2018 10-K 2020-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.